From: Treatment of primary headache in children: a multicenter hospital-based study in France
<9 years | 9–12 years | >12 years | Total | |
---|---|---|---|---|
N = 150 | N = 161 | N = 87 | N = 398 | |
Acute headache treatments, n (%) | ||||
NSAIDS | 66 (44.0) | 99 (61.5) | 48 (55.2) | 213 (53.5) |
Paracetamol | 115 (76.7) | 135 (83.9) | 77 (88.5) | 327 (82.2) |
Ergot alkaloid | 1 (0.70) | 4 (2.5) | 1 (1.2) | 6 (1.5) |
Triptan | None | 4 (2.5) | 8 (9.2) | 12 (3.0) |
Analgesics | 1 (0.7) | 3 (1.9) | 1 (1.2) | 5 (1.3) |
None | 16 (10.7) | 4 (2.5) | 2 (2.3) | 22 (5.5) |
Prophylactic treatments, n (%) | ||||
Antiserotonergics | 2 (1.3) | 8 (5.0) | 6 (6.9) | 16 (4.0) |
Tricyclics | None | 1 (0.6) | None | 1 (0.3) |
Beta blockers | None | 1 (0.6) | 1 (1.2) | 2 (0.5) |
Ca channel blockers | 1 (0.7) | 2 (1.2) | 1 (1.2) | 4 (1.0) |
Ergot alkaloids | 4 (2.7) | 12 (7.5) | 12 (13.8) | 28 (7.0) |
Antiepileptic drugs | 1 (0.7) | 1 (0.6) | None | 2 (0.5) |
No prophylaxis | 145 (96.7) | 140 (87.0) | 72 (82.8) | 357 (89.7) |